Bupropion (All indications except smoking cessation)

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Chun-Fai-Chan (Controls unexposed, NOS), 2005 Cole, 2007 Einarson, 2009 Ozturk, 2016 Anderson, 2020 51.05[0.60; 1.82]30,7981,626not evaluable Major congenital malformations Chun-Fai-Chan (Controls unexposed, NOS), 2005 Cole, 2007 Einarson, 2009 Ozturk, 2016 Anderson, 2020 51.05[0.60; 1.82]30,7981,626not evaluable Congenital heart defects Cole, 2007 Huybrechts (Controls unexposed, sick), 2014 Anderson, 2020 31.03[0.83; 1.28]1,6187,911not evaluable Ventricular septal defect Cole, 2007 Louik, 2014 Huybrechts (Controls unexposed, sick), 2014 Anderson, 2020 41.17[0.69; 1.97]3,5187,945not evaluable Atrial septal defect Louik, 2014 Anderson, 2020 21.23[0.66; 2.27]1,14221not evaluable Cleft lip with or without cleft palate Anderson, 2020 11.10[0.59; 2.05]--not evaluable Cleft palate Anderson, 2020 10.64[0.23; 1.78]--not evaluable Coarctation of aorta Louik, 2014 Anderson, 2020 21.01[0.42; 2.44]47119not evaluable Hypoplastic left heart (HLH/HLHS) Louik, 2014 Anderson, 2020 22.07[0.89; 4.79]28120not evaluable Limb defects Cole, 2007 Anderson, 2020 21.13[0.50; 2.56]101,213not evaluable Oro-facial clefts Anderson, 2020 10.94[0.53; 1.66]--not evaluable Ano-rectal atresia and stenosis Anderson, 2020 11.69[0.72; 3.98]--not evaluable Atrioventricular septal defect Louik, 2014 12.00[0.48; 8.39]52121not evaluable Cardiac septal defects Anderson, 2020 11.33[0.80; 2.21]--not evaluable Craniosynostosis Anderson, 2020 10.98[0.44; 2.19]--not evaluable Diaphragmatic hernia Anderson, 2020 12.77[1.34; 5.72]--not evaluable Ear malformations Cole, 2007 13.91[0.08; 197.23]-1,213not evaluable Eye defects Cole, 2007 111.74[0.48; 288.47]11,213not evaluable Gastroschisis Anderson, 2020 10.61[0.18; 2.05]--not evaluable Hypospadias Anderson, 2020 11.45[0.74; 2.84]--not evaluable Nervous system anomalies Cole, 2007 10.23[0.01; 3.98]81,213not evaluable Neural Tube Defects Anderson, 2020 11.45[0.73; 2.89]--not evaluable Pulmonary valve stenosis Anderson, 2020 11.19[0.53; 2.66]--not evaluable Respiratory system anomalies Cole, 2007 11.30[0.05; 32.02]11,213not evaluable Spina bifida Anderson, 2020 11.83[0.86; 3.91]--not evaluable Tetralogy of Fallot Anderson, 2020 10.99[0.35; 2.78]--not evaluable Growth parameters and prematurity Preterm (< 37 weeks) Ozturk, 2016 Marks (Controls exposed to Sertraline), 2021 22.90[0.15; 56.70]307407not evaluable Maternal consequences Preeclampsia Palmsten (Controls unexposed, sick), 2013 Newport, 2016 21.07[0.92; 1.25]3,4542,695not evaluable Postpartum hemorrhage Palmsten b, 2013 Jackson, 2024 21.33[0.99; 1.78]5,0691,217not evaluable Neonatal disorders Neonatal death (< 28 days of life) Chun-Fai-Chan (Controls unexposed, NOS), 2005 13.64[0.15; 90.25]1105not evaluable Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation Marks (Controls unexposed, sick), 2021 11.29[0.65; 2.57]-172not evaluable Jaundice / Icterus Marks (Controls exposed to Sertraline), 2021 11.15[0.85; 1.55]291406not evaluable Low Apgar score (< 7) (at 5 min) Marks (Controls exposed to Sertraline), 2021 10.95[0.68; 1.32]263406not evaluable Neonatal medical care Marks (Controls exposed to Sertraline), 2021 10.87[0.71; 1.06]475406not evaluable Neonatal tachypnea Marks (Controls exposed to Sertraline), 2021 10.81[0.56; 1.19]207406not evaluable Persistent pulmonary hypertension Marks (Controls exposed to Sertraline), 2021 10.58[0.03; 11.27]3406not evaluable Intrauterine deaths Early intrauterine deaths (< 22 weeks) / Spontaneous abortions Chun-Fai-Chan (Controls unexposed, NOS), 2005 Yaris, 2005 Kjaersgaard, 2013 Ozturk, 2016 42.63[1.09; 6.36]50138not evaluable Late intrauterine deaths (> 22 weeks) / Stillbirths Chun-Fai-Chan (Controls unexposed, NOS), 2005 12.96[0.12; 73.21]1136not evaluable Therapeutic terminations of pregnancy Chun-Fai-Chan (Controls unexposed, NOS), 2005 110.48[1.32; 83.03]11136not evaluable Elective/induced termination of pregnancy Ozturk, 2016 117.97[0.34; 938.20]141not evaluable Neuro-developmental disorders ADHD (Attention deficit hyperactivity disorder): Diagnosis Figueroa, 2010 Yeh, 2021 Suarez (Controls unexposed, discontinuers), 2022 31.62[0.65; 4.01]1,08119,462not evaluable ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk Figueroa, 2010 Yeh, 2021 Suarez (Controls unexposed, discontinuers), 2022 31.62[0.65; 4.01]1,08119,462not evaluable ASD (Autism spectrum disorder): Diagnosis Suarez (Controls unexposed, discontinuers), 2022 10.96[0.64; 1.44]18619,341not evaluable ASD (Autism spectrum disorder): Diagnosis/Risk Suarez (Controls unexposed, discontinuers), 2022 10.96[0.64; 1.44]18619,341not evaluable Cognitive developmental disorders/delay (3-6 years old) Suarez (Controls unexposed, discontinuers), 2022 11.99[0.90; 4.39]2112,756not evaluable Language disorders/delay Suarez (Controls unexposed, discontinuers), 2022 11.10[0.91; 1.33]90319,341not evaluable Learning disorders Suarez (Controls unexposed, discontinuers), 2022 10.93[0.53; 1.63]8219,341not evaluable Neuro-developmental disorders (as a whole) Suarez (Controls unexposed, discontinuers), 2022 11.07[0.94; 1.21]2,00319,341not evaluable Psychomotor developmental disorders/delay Suarez (Controls unexposed, discontinuers), 2022 11.91[1.16; 3.14]13119,341not evaluable Severe cognitive developmental delay (Mental retardation) (3-6 years old) Suarez (Controls unexposed, discontinuers), 2022 11.99[0.90; 4.39]2112,756not evaluable0.0100.01.0

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons